Although the LLC tumor growth was restrained by FFAR2 inhibitor and anti-PD-1 antibody respectively, the combination therapy dramatically enhanced this inhibition on both tumor size and weight (Fig. 7A–C), and extended the survival of tumor-bearing mice (Fig. 7D). Here, FFAR2 is linked to neoplasm.